🇺🇸 FDA
Patent

US 10947317

NaPi2b-targeted antibody-drug conjugates and methods of use thereof

granted A61KA61K47/6805A61K47/6811

Quick answer

US patent 10947317 (NaPi2b-targeted antibody-drug conjugates and methods of use thereof) held by Mersana Therapeutics, Inc. expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Mersana Therapeutics, Inc.
Grant date
Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K47/6805, A61K47/6811, A61K47/6851, A61K47/6857